NIPH Clinical Trials Search

UMIN ID: C000000257

Registered date:30/09/2005

Randomized study comparing six times of epirubicin instillation for 2.5 months with six times for two weeks in superficial bladder cancer after transurethral resection of bladder tumor

Basic Information

Recruitment status Complete: follow-up continuing
Health condition(s) or Problem(s) studiedSuperficial bladder cancer
Date of first enrollment2002/05/01
Target sample size300
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)40mg Epirubicin / 40ml sailine weekly instillation for two weeks, then bi-weekly instillation for 8weeks 40mg Epirubicin / 40ml sailine three daily instillation a week for two weeks


Primary OutcomeRecurrence
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteriaSynchronous CIS G3 tumor Severe complication History of allergy for Epirubicin Active infection Active synchronous malignancy History of upper urinary tract malignancies

Related Information


public contact
Name Hideyuki Akaza MD
Address Japan
Telephone 029-853-3223
Affiliation University of Tsukuba Department of Urology
scientific contact
Name Yoshihiko Hirao MD
Address Nara Japan
Affiliation Nara Medical University Department of Urology